<article article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11161394</article-id><article-id pub-id-type="pmc">2363753</article-id><article-id pub-id-type="pii">6691611</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1611</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplanation<xref ref-type="other" rid="tlnote1"></xref></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hartmann</surname><given-names>J T</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Vangerow</surname><given-names>A von</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fels</surname><given-names>L M</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Knop</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Stolte</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Kanz</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bokemeyer</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Dept. of Hematology and Oncology, UKT-Medical Center II, Eberhard-Karls-University of Tübingen, Tübingen, 72076</aff><aff id="aff2"><label>2</label>Division of Nephrology, University Medical School Hannover, Hannover, 30625</aff><aff id="aff3"><label>3</label>Society for Science and Technology Transfer (GWT e.V.), Gosen, Berlin, 15537, Germany</aff><pub-date pub-type="ppub"><month>02</month><year>2001</year></pub-date><volume>84</volume><issue>3</issue><fpage>313</fpage><lpage>320</lpage><history><date date-type="received"><day>21</day><month>06</month><year>2000</year></date><date date-type="rev-recd"><day>05</day><month>10</month><year>2000</year></date><date date-type="accepted"><day>27</day><month>10</month><year>2000</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p><offsets xml_i="3087" xml_f="3498" txt_i="11" txt_f="422">This pilot study evaluates the degree of side effects during high-dose chemotherapy (HD-VIC) plus autologous bone marrow transplant (HDCT) and its possible prevention by the cytoprotective thiol-derivate amifostine. Additionally, the in-patient medical costs of both treatment arms were compared. 40 patients with solid tumours were randomized to receive HD-VIC chemotherapy with or without amifostine (910 mg/m</offsets><sup><offsets xml_i="3503" xml_f="3504" txt_i="422" txt_f="423">2</offsets></sup><offsets xml_i="3510" xml_f="3697" txt_i="423" txt_f="610"> at day 1–3) given as a short infusion prior to carboplatin and ifosfamide. Patients were stratified according to pretreatment. HDCT consisted of an 18 h infusion of carboplatin (500 mg/m</offsets><sup><offsets xml_i="3702" xml_f="3704" txt_i="610" txt_f="612">2/</offsets></sup><offsets xml_i="3710" xml_f="3741" txt_i="612" txt_f="643">d over 18 h), ifosfamide (4 g/m</offsets><sup><offsets xml_i="3746" xml_f="3747" txt_i="643" txt_f="644">2</offsets></sup><offsets xml_i="3753" xml_f="3789" txt_i="644" txt_f="680">/d over 4 h) and etoposide (500 mg/m</offsets><sup><offsets xml_i="3794" xml_f="3795" txt_i="680" txt_f="681">2</offsets></sup><offsets xml_i="3801" xml_f="3903" txt_i="681" txt_f="783">/d) all given for 3 consecutive days. All patients received prophylactic application of G-CSF (5 μg kg</offsets><sup><offsets xml_i="3908" xml_f="3910" txt_i="783" txt_f="785">−1</offsets></sup><offsets xml_i="3916" xml_f="4241" txt_i="785" txt_f="1110"> subcutaneously) to ameliorate neutropenia after treatment. Patients were monitored for nephrotoxicity, gastrointestinal side effects, haematopoietic recovery, as well as frequency of fever and infections. The median fall of the glomerular filtration rate (GFR) was 10% from baseline in the amifostine group (105 to 95 ml min</offsets><sup><offsets xml_i="4246" xml_f="4248" txt_i="1110" txt_f="1112">−1</offsets></sup><offsets xml_i="4254" xml_f="4310" txt_i="1112" txt_f="1168">) and 37% in the control patient group (107 to 67 ml min</offsets><sup><offsets xml_i="4315" xml_f="4317" txt_i="1168" txt_f="1170">−1</offsets></sup><offsets xml_i="4323" xml_f="4326" txt_i="1170" txt_f="1173">) (</offsets><italic><offsets xml_i="4334" xml_f="4335" txt_i="1173" txt_f="1174">P</offsets></italic><offsets xml_i="4344" xml_f="4571" txt_i="1174" txt_f="1398">&lt; 0.01). Amifostine-treated patients revealed a less pronounced increase in albumine and low molecular weight protein urinary excretion. Stomatitis grade III/IV occurred in 25% without versus 0% of patients with amifostine (</offsets><italic><offsets xml_i="4579" xml_f="4580" txt_i="1398" txt_f="1399">P</offsets></italic><offsets xml_i="4589" xml_f="4762" txt_i="1399" txt_f="1572"> = 0.01). Acute nausea/vomiting was frequently observed immediately during or after the application of amifostine despite intensive antiemetic prophylaxis consisting of 5-HT</offsets><sub><offsets xml_i="4767" xml_f="4768" txt_i="1572" txt_f="1573">3</offsets></sub><offsets xml_i="4774" xml_f="4936" txt_i="1573" txt_f="1732">-receptor antagonists/dexamethasone/trifluorpromazine. However, delayed emesis occurred more often in the control patients. Engraftment of neutrophil (&gt; 500 μl</offsets><sup><offsets xml_i="4941" xml_f="4943" txt_i="1732" txt_f="1734">−1</offsets></sup><offsets xml_i="4949" xml_f="4983" txt_i="1734" txt_f="1765">) and thrombocytes (&gt; 25 000 μl</offsets><sup><offsets xml_i="4988" xml_f="4990" txt_i="1765" txt_f="1767">−1</offsets></sup><offsets xml_i="4996" xml_f="6048" txt_i="1767" txt_f="2819">)were observed at days 9 versus 10 and 10 versus 12, respectively, both slightly in favour of the amifostine arm. In addition, a lower number of days with fever and a shortened duration of hospital stay were observed in the amifostine arm. The reduction of acute toxicity observed in the amifostine arm resulted in 30% savings in costs for supportive care (Euro 4396 versus Euro 3153 per patient). Taking into account the drug costs of amifostine, calculation of in-patient treatment costs from the start of chemotherapy to discharge revealed additional costs of Euro 540 per patient in the amifostine arm. This randomized pilot study indicates that both organ and haematotoxicity of HD-VIC chemotherapy can be ameliorated by the use of amifostine. Additionally, a nearly complete preservation of GFR was observed in amifostine-treated patients which may be advantageous if repetitive cycles of HDCT are planned. Larger randomized trials evaluating amifostine cytoprotection during high-dose chemotherapy are warranted. © 2001 Cancer Research Campaign </offsets><ext-link ext-link-type="uri" xlink:href="http://www.bjcancer.com"><offsets xml_i="6115" xml_f="6138" txt_i="2819" txt_f="2842">http://www.bjcancer.com</offsets></ext-link></p></abstract><kwd-group><kwd>toxicity</kwd><kwd>high-dose chemotherapy</kwd><kwd>PBSC transplantation</kwd><kwd>cytoprotection</kwd><kwd>amifostine</kwd><kwd>pharmacoeconomics</kwd></kwd-group></article-meta></front><back><fn-group><fn id="tlnote1"><p>Presented in part at the 35th Proceedings of the American Society of Clinical Oncology, Atlanta, Georgia, USA, May 15–18, 1999. This work represents part of the thesis of A. von Vangerow at the Dept. Hematology/Oncology, University of Tübingen.</p></fn></fn-group></back></article>